SureTrader Nadex Advertisement SureTrader
Home > Boards > US Listed > Medical - Healthcare >

Biocept, Inc. (BIOC)

Add BIOC Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 4/22/2017 7:32:13 AM - Followers: 62 - Board type: Free - Posts Today: 0

Biocept, Inc., headquartered in San Diego, California, is a commercial-stage oncology diagnostics company focused on providing information on patients' tumors to physicians using its proprietary technology platform to help improve individual patient treatment. Biocept has developed proprietary technology platforms for capture and analysis of circulating tumor DNA, both in circulating tumor cells (CTCs) and in plasma (cell free tumor DNA or ctDNA). A standard blood sample is utilized to provide physicians with important prognostic and predictive information to enhance individual treatment of their patients with cancer. Biocept currently offers its OncoCEE-BRTM test for breast cancer and OncoCEE-LUTM for non-small cell lung cancer and OncoCEE- GATM for Gastric Cancer and plans to introduce additional CLIA validated tests for breast, lung, colorectal, melanoma, prostate and other solid tumors based on its proprietary technology platforms over the coming months.


The Leader in Clinical Trial Management Solutions

BioClinica accelerates the development of new medical therapies by delivering expertise and technologies that enhance clinical research, worldwide. Our industry-leading Medical Imaging services, Cardiac Safety, and enterprise eClinical platform bring a new level of quality and efficiency to every phase of clinical development. Our experience spans three decades and includes thousands of studies in all therapeutic areas, from design and management, through submission and post-approval. BioClinica serves more than 400 pharmaceutical, biotechnology, and device companies – including all the top 20 - through a network of offices in the U.S., Europe, and Asia.


IRT Sourcing Models, Breaking with Convention (Part 2)

Submitted by Steve Goldstein on February 18, 2015 - 4:34pm

What Makes an IRT Great for Technology Transfer?

In the last blog we talked about how technology transfer is gaining ground on the conventional Software as a Service (SaaS) IRT sourcing model. In this blog post, I will explain the advantages of the technology and design behind Trident that make it particularly well-suited for IRT technology transfer. So let's dive right in.

IRT Sourcing Models, Breaking with Convention (Part 1)

Submitted by Steve Goldstein on February 18, 2015 - 4:02pm

Technology Transfer Gaining on Saas

When it comes to Interactive Response Technology (IRT) – systems used to perform subject randomization, drug dispensing and study drug resupply – Software as a Service (SaaS) continues to be the conventional delivery model including here at BioClinica.

Key Insights from SCDM Euro Leadership Forum

Submitted by Jonathan Andrus on February 6, 2015 - 4:15pm

Break-out Group Dissects the Development of a Risk-Based Approach To Clinical Trial Management

As SCDM's 2014 Chair I had the honor of presenting the keynote at the EU Leadership Forum held in The Netherlands, December 2014. Celebrating the organization's 20th Anniversary and all that's been accomplished, we took a light-hearted look at the Evolution of the Clinical Data Management Role.

Escalating Role of Medical Imaging in AD Clinical Trials

Submitted by Eli Berdougo on January 30, 2015 - 1:12pm

Studies Reveal Impact of Implementing, Standardizing, and Developing Neuroimaging Endpoints in Alzheimer's Disease Trials

Alzheimer's disease is one of the most important health challenges facing aging populations worldwide. Disease modifying therapies are desperately needed and many potential treatments are currently being tested in clinical trials. The role and impact of medical imaging in AD trials continues to grow, especially as clinicians and scientists seek to define and treat AD at the earliest stages of disease.

Risk-Based Monitoring Technology: 5 Essential Capabilities

Submitted by Courtney McBean on January 27, 2015 - 2:05pm

If you've spent time researching risk-based monitoring (RBM) over the past year, you know dozens of academics, CROs, clinical trial practitioners, and statisticians have proposed varied approaches based on sponsor needs and trial designs. Unfortunately, despite an abundance of theoretical perspectives on RBM, clinical trial teams soon discover a significant gap still exists between perspectives and actual tools to enable real-world RBM implementation.

Time to Take Action and Make Risk-Based Monitoring a Reality

Submitted by Courtney McBean on January 19, 2015 - 12:23pm

Intense interest surrounding RBM shows alignment of all the right elements — technology, regulatory bodies and the industry itself – to make risk-based monitoring a reality. If implemented with the right components, this approach could result in the most efficient trial management possible.

What’s New with CDISC Standards?

Submitted by Jennifer Price on December 16, 2014 - 11:13am

Progress on CDISC Standards has come at a quickened pace in recent years. Helping make advancement of industry-wide standards possible is collaboration among CDISC and other participating organizations (Critical Path Institute, Association of Clinical Research Organizations, Innovative Medicines Initiative, and National Cancer Institute). Joining in the collaboration are regulatory authorities and the pharma industry itself, as well as TransCelerate Biopharma which continues to press forward with its standards initiative.

Evolution of the Clinical Data Management Role, 1994-2014

Submitted by Jonathan Andrus on December 9, 2014 - 12:11pm

20-Year Retrospective

The role of the Clinical Data Manager (CDM) has changed immensely since 1994, both in terms of role and function. Let's take a fun retrospective look at the great strides made in our field over these last 20 years, and more importantly, where the CDM role is headed. Let's begin with 1994, in honor of the Society of Clinical Data Management (SCDM), which commemorated its 20th Anniversary in 2014.

3 Reasons to Share Data from Unsuccessful Clinical Trials

Submitted by Eli Berdougo on November 25, 2014 - 4:53pm
3 Reasons to Share Data from Unsuccessful Clinical Trials

A recent proposal by the U.S. Department of Health and Human Services (HHS) could expand the amount of clinical trial data that drug companies must share with the public. Under the proposal, clinical trial sponsors would be required to report findings for drugs and devices that fail to reach approval.

eSource: Are You On-Trend with Other Sponsors?

Submitted by Jennifer Price on November 12, 2014 - 11:17am

eSource is a topic that has everyone talking and it continues to dominate the conversation at industry gatherings, including the annual SCDM conference held earlier this fall. From what I heard there − and continue to hear – sponsors' experience with eSource runs the full gamut.

Why 'Intelligent Monitoring' Is Even Smarter than Risk-Based Monitoring

Submitted by Courtney McBean on October 31, 2014 - 1:27pm

When I speak on the topic of risk-based monitoring (RBM) at industry events, someone invariably comes up afterward to say how nice it is we finally stopped talking about risk-based monitoring!

eSource: Still in the Shallow End of the Pool?

Submitted by Jennifer Price on October 23, 2014 - 3:25pm

Dipping a toe in the water is always easier than jumping right into something new.

I am reminded of this old axiom as I look back at the recent SCDM conference and see it holds true for eSource.

Testing different eSource modalities within a controlled environment is one way to get acclimated and explore the use of eSource in your clinical trials while building experience – all in a low-risk way. Beginning with data that's directly entered as eSource is a whole lot easier and safer than attempting to hit it 100 percent from the high dive on the first try.

7 Principles of eSource Use

Submitted by Jennifer Price on October 17, 2014 - 10:31am
7 Principles of eSource Use

As I write this, I’m on a return flight home to Philadelphia from Las Vegas where I attended the Annual SCDM conference. It was a great event and I’m pretty revved up to share what I saw and heard there, especially on the evolving topic of eSource.

One session I’d like to tell you about is an eSource roundtable that was moderated by Linda King, Director of Global Data Delivery at Eli Lilly and Demetris Zambas, VP and Global Head, Data Management at Novartis. Representatives from CDISC, Merck, J&J, AssisTek, Quintiles, and Otsuka rounded out the expert panel.

Response to TransCelerate’s Risk-Based Monitoring Paper: Technology Considerations to Enable Risk-Based Monitoring Methodology

Submitted by Courtney McBean on September 30, 2014 - 1:46pm

Have you had a chance to read the latest TransCelerate paper on risk-based monitoring (RBM)?

If not, I highly recommend getting your eyes on Technology Considerations to Enable the Risk-Based Monitoring Methodology, published online in August on behalf of the Drug Information Association (DIA). This paper serves as a tremendous resource for any organization interested in new enterprise technology to help realize the advantages of risk-based monitoring.

Highlights from the 2014 Osteoarthritis Imaging Workshop

Submitted by Eli Berdougo on September 23, 2014 - 2:58pm
Highlights from the 2014 Osteoarthritis Imaging Workshop

This summer, experts from academia, industry and regulatory sectors gathered in Reykjavik, Iceland for The International Workshop on Osteoarthritis Imaging (IWOAI) to discuss the latest advances related to imaging in Osteoarthritis (OA). Presentations at this conference centered on new imaging techniques and analytical methods for monitoring OA pathophysiology and evaluating imaging data from clinical studies.

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
BIOC News: Biocept Awarded Additional Patent in Japan Expanding Intellectual Property Estate to 19 Issued Patents Protecting Its Target ... 04/18/2017 08:05:00 AM
BIOC News: Small Company Offering and Sale of Securities Without Registration (d) 04/10/2017 06:06:25 AM
BIOC News: Statement of Changes in Beneficial Ownership (4) 04/03/2017 07:10:36 PM
BIOC News: Statement of Changes in Beneficial Ownership (4) 04/03/2017 07:09:10 PM
BIOC News: Statement of Changes in Beneficial Ownership (4) 04/03/2017 07:08:24 PM
#1238   I've been distracted by other stocks. It digiholic 04/22/17 07:32:12 AM
#1237   Bought back in today. IMO we should see Ace508 04/21/17 05:45:57 PM
#1236   Right on... Long_Long_Fellow 04/03/17 08:20:25 AM
#1235   Fully anticipate a major announcement (likely a new tman00 03/28/17 10:45:40 AM
#1234   BIOC bullish 2.21 stocktrademan 03/24/17 01:22:19 PM
#1233   * * $BIOC Video Chart 03-22-17 * * ClayTrader 03/22/17 05:39:07 PM
#1232   Big news today $$$ BIOC $$$ Ace508 03/14/17 08:14:05 PM
#1231   bought 20k back in jan under a worries!!! dirtydozen911 03/10/17 05:54:54 PM
#1230   Yeah, some just don't understand the debt of digiholic 03/10/17 12:16:04 PM
#1229   short volume ratio on bioc______.64...squeeze????? dirtydozen911 03/08/17 09:15:15 AM
#1228   Go read his other posts. Everything is audeuce02 03/06/17 01:49:32 PM
#1227   Feb. 13th - Make no mistake about it. tjguy 03/05/17 08:19:25 PM
#1226   BIOC similar pattern as yesterday. Will ramp tman00 03/02/17 12:36:43 PM
#1225   I can assure everyone of at least 88K tman00 03/01/17 04:17:21 PM
#1224   First green day in a while + held tman00 02/22/17 04:04:11 PM
#1223   Only question that needs to be asked is eneels01 02/18/17 08:32:03 AM
#1222   This stock you have to play on the digiholic 02/16/17 08:43:26 AM
#1221   Lmfao. What an illegally traded pos stock. Tbone88 02/15/17 03:07:45 PM
#1220   What a manipulated PoS. It spikes then gets Tbone88 02/15/17 01:31:10 PM
#1219   Only real support for this one is around Kraken3 02/14/17 10:56:44 AM
#1218   Reporting this fraudulent trading activity to the SEC. Tbone88 02/14/17 10:54:50 AM
#1217   Booooommmmm Tbone88 02/13/17 01:30:08 PM
#1216   Thanks you for the teens. Miracle of Tbone88 02/13/17 09:38:41 AM
#1215   This is pre big boy buying. Make Tbone88 02/13/17 08:25:00 AM
#1214   I'll bet you.... Tbone88 02/13/17 08:15:29 AM
#1213   This will tank today IMO Freemo 02/13/17 05:55:58 AM
#1212   This sick always defies gravity one day, then digiholic 02/12/17 07:01:03 AM
#1211   Anyone who sold today is going to be Tbone88 02/10/17 09:16:54 PM
#1210 Ace508 02/10/17 04:07:10 PM
#1209   Shorts are shorting the wrong stock here. Tbone88 02/10/17 03:49:57 PM
#1208   How does a stock get taken down on Tbone88 02/10/17 03:40:15 PM
#1207   Anyone know when their 10q is due? 19thgreen 02/10/17 01:30:03 PM
#1206   Picked up a chunk. I like this one THE GOLD STANDARD 02/10/17 01:19:42 PM
#1205   Looking good and holding support $Bullish xlogit3k 02/10/17 12:20:09 PM
#1204   Out at 2.7 this am, considering re-entry ApexTrend 02/10/17 12:09:13 PM
#1203   Man they really are loading up the boat!! Tbone88 02/10/17 10:50:26 AM
#1202   We will see 3 if these sleezy mms Tbone88 02/10/17 10:44:19 AM
#1201   Helped me get more cheap shares! Will gimmekimmy 02/10/17 09:59:15 AM
#1200   A few complete morons selling pre market like bozos Tbone88 02/10/17 08:18:42 AM
#1199   Pre market is killin it Triple nickle 02/10/17 07:44:05 AM
#1198   Yeah she definitely did StockWhale 02/09/17 08:26:41 PM
#1197   Nice swing fellas, looking good into tomorrow ApexTrend 02/09/17 07:58:32 PM
#1196   Wow she kept going lol im good at mikekrane 02/09/17 06:51:28 PM
#1195   Looking good StockWhale 02/09/17 06:32:56 PM
#1194   Yes, today it is fun lol. Glad I ApexTrend 02/09/17 06:15:03 PM
#1193   Sorry meant fun xlogit3k 02/09/17 05:34:09 PM
#1192   What is trading gun? ApexTrend 02/09/17 05:33:04 PM
#1191   New trader, is AH trading gun? xlogit3k 02/09/17 05:30:56 PM
#1190   BIOC 2.43 AH strong PAC 02/09/17 05:30:03 PM
#1189   Ripping AH! ApexTrend 02/09/17 04:48:22 PM